Abstract
To investigate the modulatory roles of central γ-aminobutyric acid (GABA)A and GABAB receptors in the regulation of basal and stress-induced plasma interleukin-6 (IL-6) levels, we examined the effects of i.c.v. injection of GABA receptor agonists and antagonists on basal and restraint stress-induced plasma IL-6 levels in mice. Muscimol (20–200 ng), a GABAA receptor agonist, and baclofen (5–20 ng), a GABAB receptor agonist, injected i.c.v. did not affect the basal levels of plasma IL-6. In the restraint-stressed animals, muscimol and baclofen inhibited the stress-induced plasma IL-6 levels from the dose of 50 and 15 ng, respectively. 2-(3-Carboxyl)-3-amino-6-(4-methoxyphenyl)-pyridazinium bromide (SR-95,531; 0.3–10 ng), a GABAA receptor antagonist, and 2-hydroxysaclofen (1–10 μg), a GABABreceptor antagonist, injected i.c.v. increased both the basal and the restraint stress-induced plasma IL-6 levels. The i.p. pretreatment of animals with 6-hydroxydopamine (100 mg/kg) for 3 days significantly inhibited SR-95,531 (3 ng i.c.v.)- but not 2-hydroxysaclofen (10 μg i.c.v.)-induced increase in the basal plasma IL-6 levels. These data suggest that central GABAA and GABAB receptors are involved in the suppressive modulation of basal and restraint stress-induced plasma IL-6 levels in mice.
Footnotes
-
Send reprint requests to: Dr. Dong-Keun Song, Department of Pharmacology, College of Medicine, Hallym University, Chunchon, Kangwon-Do, 200-702, South Korea.
-
↵1 This study was supported by Interdisciplinary Research Grants (95-0403-19-01-3, 96-0403-16-01-3) from the Korea Science and Engineering Foundation (KOSEF).
- Abbreviations:
- IL-6
- interleukin-6
- NMDA
- N-methyl-d-aspartate
- GABA
- γ-aminobutyric acid
- SR-95
- 531, 2-(3-carboxypropyl)-3-amino-6-(4-methoxyphenyl)-pyridazinium bromide
- MK-801
- (+)-5-methyl-10,11-dihydro-5H-dibenzo(a,d)cyclopepten-5,10-imine maleate
- IL-1β
- interleukin-1β
- TNF-α
- tumor necrosis factor-α
- 6-OHDA
- 6-hydroxydopamine
- Received November 17, 1997.
- Accepted May 19, 1998.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|